Correspondence
Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study
I.E. Deckers,
Corresponding Author
I.E. Deckers
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Department of Immunology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author H.H. van der Zee,
H.H. van der Zee
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author D.M.W. Balak,
D.M.W. Balak
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author E.P. Prens,
E.P. Prens
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Department of Immunology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author
I.E. Deckers,
Corresponding Author
I.E. Deckers
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Department of Immunology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author H.H. van der Zee,
H.H. van der Zee
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author D.M.W. Balak,
D.M.W. Balak
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author E.P. Prens,
E.P. Prens
Department of Dermatology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Department of Immunology, Erasmus University Medical Center, Burg. s’ Jacobplein 51, 3015 CA Rotterdam, The Netherlands
Search for more papers by this author
First published: 13 August 2014
No abstract is available for this article.
References
- 1Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatology Venereol 2009; 23: 985–98.
- 2Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91: 328–32.
- 3Pathirana D, Ormerod AD, Saiag P et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatology Venereol 2009; 23: 1–70.
- 4Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005; 11: 43–8.
- 5Van der Zee HH, de Ruiter L, van den Broecke DG et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292–8.
- 6Van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 21: 735–9.
- 7Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007; 57: 1059–68.
- 8Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790–8.
- 9Ghoreschi K, Brück J, Kellerer C et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208: 2291–303.
- 10Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor κB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein β in activated human T cells. Br J Dermatol 2007; 156: 838–42.